Correlation of ER, PgR, HER-2/neu, p53, and VEGF with clinical characteristics and prognosis in chinese women with invasive breast cancer

Breast Journal

Volumn 14, Issue 3, 2008, Pages 308-310

  Lu, Xiaowei ^a   Gu, Yumei ^b   Ding, Yun ^a   Song, Wei ^a   Mao, Jinfeng ^a   Tan, Jianxin ^b   Zhao, Hua ^a   Han, Xiao ^b   Sun, Yujie ^b  

^a Department of Breast Surgery   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER; VASCULOTROPIN;

BREAST CANCER; CANCER INCIDENCE; CANCER RELAPSE; CHINESE; CLINICAL FEATURE; LETTER; METASTASIS; PROGNOSIS;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHINA; FEMALE; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 43549096884     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2008.00583.x     Document Type: Letter

References (16)

1. Britta W, Johannes L, Peterse JL, et al. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005 5 : 591 602.
2. Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989 7 : 1239 51.
3. Hellman S. Natural history of small breast cancers (Karnofsky Memorial Lecture). J Clin Oncol 1994 12 : 2229 34.
4. Andrea N, Angelo C, Giulio T. Biomolecular markers of breast cancer. Front Biosci 2006 11 : 1818 43.
5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001 2 : 127 37.
6. Keohavong P, Gao WM, Mady HH, et al. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Cancer Lett 2004 212 : 121 30.
7. Linderholm B, Lindh B, Tavelin B, et al. p53 and vascular endothelial growth factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000 89 : 51 62.
8. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997 89 : 139 47.
9. Toi M, Inada K, Suzuki H, et al. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995 36 : 193 204.
10. Vander AI, Benoy I, Colpaert CG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004 10 : 7965 71.
11. Chelouche LD, Miller CP, Tellez C, et al. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur J Cancer 2004 40 : 2509 18.
12. Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer 2000 88 : 114 23.
13. Chuang SC, Chen W, Hashibe M, et al. Survival rates of invasive breast cancer among ethnic Chinese women born in East Asia and the United States. Asian Pac J Cancer Prev 2006 7 : 221 6.
14. Blackman DJ, Masi CM. Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? J Clin Oncol 2006 24 : 2170 8.
15. Woods SE, Luking R, Atkins B, et al. Association of race and breast cancer stage. J Natl Med Assoc 2006 98 : 683 6.
16. National Coordinating Group for Breast Screening Pathology. Pathology Reporting in Breast Cancer Screening, 2nd edn. Sheffield : NHSBSP Publications, 1995.